Cingulate Inc是一家臨床階段的生物製藥公司。該公司專注於利用精確定時釋放(PTR)藥物輸送平台技術開發,製造和商業化藥品,以創建劑量計劃和藥物釋放曲線,改善患有多種常見疾病的患者的生活。該公司專注於注意力缺陷/多動障礙(ADHD)的治療。該公司正在開發兩種主要候選產品,如CTx-1301(右哌甲酯)和CTx-1302(右旋安非他明)。其CTx-1301和CTx-1302候選藥物均含有三種釋放的活性藥物成分,組合成一種小片劑型。其CTx-1301和CTx-1302正在開髮用於治療ADHD的三個核心患者部分:兒童(6-12歲),青少年(13-17歲)和成人(18歲以上)。
名稱 | 主旨 | 成立於 | 年齡 |
|---|---|---|---|
| Shane J. Schaffer | Co-Founder, CEO & Chairman of the Board | 2026 | 51 |
| Jeff Hargroves | Lead Independent Director | 2026 | 59 |
| Bryan Jay Lawrence | Independent Director | 2024 | 60 |
| Zhanpeng Jiang | Independent Director | 2026 | 56 |
| Peter J. Werth | Director | 2018 | 87 |
| Ann Childress | Member of Scientific Advisory Board | - | - |
| Brian D. Barash | Member of Scientific Advisory Board | - | - |
| Andrew J. Cutler | Member of Scientific Advisory Board | - | 65 |
| Laurence L. Greenhill | Member of Scientific Advisory Board | - | - |
| John S. Markowitz | Member of Scientific Advisory Board | - | - |
| Dinohra Munoz-Silva | Member of Scientific Advisory Board | - | - |
| Jeffrey Newcorn | Member of Scientific Advisory Board | - | - |
| Declan Quinn | Member of Scientific Advisory Board | - | - |
| Sharon B. Wigal | Member of Scientific Advisory Board | - | - |
| Alice Mao | Member of Scientific Advisory Board | - | - |